Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0091 | 0 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0182 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0182 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0182 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0182 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0182 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0182 | 1 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0092 | 0.0151 | 0.0151 |
Brugia malayi | FAD binding domain containing protein | 0.0182 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0091 | 0 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0162 | 0.7743 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0182 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0113 | 0.2407 | 0.2407 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0182 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0113 | 0.2407 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0182 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0162 | 0.7743 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0182 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0182 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0182 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0182 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0182 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0182 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0182 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0182 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0182 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0182 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0182 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0182 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Cures (functional) | = 1 | Suppressive blood schizonticidal antimalarial activity evaluated in the trophozoite-induced Plasmodium berghei infection in mice at a dose 80 mg/kg given as no. of cures | ChEMBL. | 3599024 |
Cures (functional) | = 2 | Suppressive blood schizonticidal antimalarial activity evaluated in the trophozoite-induced Plasmodium berghei infection in mice at a dose 20 mg/kg given as no. of cures | ChEMBL. | 3599024 |
Cures (functional) | = 3 | Blood schizonticidal antimalarial activity in trophozoite-induced Plasmodium berghei infection in mice at a dose of 40 mg/kg given as no. of cures. | ChEMBL. | 3599024 |
Cures (functional) | = 1 | Suppressive blood schizonticidal antimalarial activity evaluated in the trophozoite-induced Plasmodium berghei infection in mice at a dose 80 mg/kg given as no. of cures | ChEMBL. | 3599024 |
Cures (functional) | = 2 | Suppressive blood schizonticidal antimalarial activity evaluated in the trophozoite-induced Plasmodium berghei infection in mice at a dose 20 mg/kg given as no. of cures | ChEMBL. | 3599024 |
Cures (functional) | = 3 | Blood schizonticidal antimalarial activity in trophozoite-induced Plasmodium berghei infection in mice at a dose of 40 mg/kg given as no. of cures. | ChEMBL. | 3599024 |
Cures/no. of animals (functional) | = 1 | Radical curative antimalarial activity against Plasmodium cynomolgi in rhesus monkeys expressed as number of cures/no. of animals at a daily dose of 1 mg/kg (x7); 1/1 | ChEMBL. | 3599024 |
Delta MST (functional) | = 6.1 | Suppressive blood schizonticidal antimalarial activity evaluated in the trophozoite-induced Plasmodium berghei infection in mice at a dose 10 mg/kg | ChEMBL. | 3599024 |
Delta MST (functional) | = 6.1 | Suppressive blood schizonticidal antimalarial activity evaluated in the trophozoite-induced Plasmodium berghei infection in mice at a dose 10 mg/kg | ChEMBL. | 3599024 |
Toxic deaths (functional) | = 5 | Suppressive blood schizonticidal antimalarial activity evaluated in the trophozoite-induced Plasmodium berghei infection in mice at a dose 160 mg/kg given as no. of toxic deaths | ChEMBL. | 3599024 |
Toxic deaths (functional) | = 5 | Suppressive blood schizonticidal antimalarial activity evaluated in the trophozoite-induced Plasmodium berghei infection in mice at a dose 320 mg/kg given as no. of toxic deaths | ChEMBL. | 3599024 |
Toxic deaths (ADMET) | = 5 | Suppressive blood schizonticidal antimalarial activity evaluated in the trophozoite-induced Plasmodium berghei infection in mice at a dose 640 mg/kg given as no. of toxic deaths | ChEMBL. | 3599024 |
Toxic deaths (functional) | = 5 | Suppressive blood schizonticidal antimalarial activity evaluated in the trophozoite-induced Plasmodium berghei infection in mice at a dose 160 mg/kg given as no. of toxic deaths | ChEMBL. | 3599024 |
Toxic deaths (functional) | = 5 | Suppressive blood schizonticidal antimalarial activity evaluated in the trophozoite-induced Plasmodium berghei infection in mice at a dose 320 mg/kg given as no. of toxic deaths | ChEMBL. | 3599024 |
Toxic deaths (ADMET) | = 5 | Suppressive blood schizonticidal antimalarial activity evaluated in the trophozoite-induced Plasmodium berghei infection in mice at a dose 640 mg/kg given as no. of toxic deaths | ChEMBL. | 3599024 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.